

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/NF16E222EE8EN.html>

Date: March 2020

Pages: 147

Price: US\$ 2,000.00 (Single User License)

ID: NF16E222EE8EN

Abstracts

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Pipeline Review, H1 2020, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person's immune system (the body's natural defense against infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key

players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 6, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Neuromyelitis Optica (Devic's Syndrome) - Overview

Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Development

Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment

Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics
Development

Neuromyelitis Optica (Devic's Syndrome) - Drug Profiles

Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects

Neuromyelitis Optica (Devic's Syndrome) - Discontinued Products

Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Accendatech Au Pty Ltd, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Ahead Therapeutics SL, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Apsara Therapeutics, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bio-Thera Solutions Ltd, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma SL, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Boston Pharmaceuticals Inc, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chord Therapeutics Sarl, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H1 2020

Neuromyelitis Optica (Devic's Syndrome) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Accendatech Au Pty Ltd

Ahead Therapeutics SL

Alexion Pharmaceuticals Inc

Apsara Therapeutics

Bio-Thera Solutions Ltd

Biogen Inc

Bionure Farma SL

Boston Pharmaceuticals Inc

Chord Therapeutics Sarl

Chugai Pharmaceutical Co Ltd

Cour Pharmaceuticals Development Co Inc

Endece LLC

EnhanX Biopharm Inc

H. Lundbeck AS

HanAll Biopharma Co Ltd

ImCyse SA

Imstem Biotechnology Inc

LFB SA

Mitsubishi Tanabe Pharma Corp

NovelMed Therapeutics Inc

Orion BioScience Inc
RemeGen Ltd
Tolerion Inc
Viela Bio Inc

I would like to order

Product name: Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/NF16E222EE8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NF16E222EE8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970